Clinical Trials Logo

Fungemia clinical trials

View clinical trials related to Fungemia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT03876990 Completed - Fungemia Clinical Trials

Clinical and Medico-economic Evaluation of a Rapid Test (ePlex-BCID®, GenMark) for the Diagnosis of Bacteremia and Fungemia.

HEMOFAST
Start date: June 20, 2019
Phase: N/A
Study type: Interventional

This study evaluates the clinical benefit of a rapid test for fast diagnosis of bacteremia and fungemia from positive blood cultures in case of sepsis. This assay enables rapid identification of bacteria and fungi and allows to evaluate bacterial resistance to first line antibiotics. The clinical and medico-economic impact of this assay used in addition to the current diagnosis strategy (half of the patients) will be compared to the current diagnostic strategy alone (other half of the patient).

NCT ID: NCT03827330 Completed - Candida Fungemia Clinical Trials

Retrospective Chart Review of Candida Fungemia

Start date: January 3, 2019
Phase:
Study type: Observational

Background: Candida can cause infections. The most common kind of Candida at clinics is C albicans. But other kinds have increased at clinics too. Researchers want to review the records of people who were in previous NIH studies who had Candida. They want to find out what risk factors are associaated with this infection. Objective: To study the factors that are associated with Candida fungemia to develop. The factors are clinical features, diagnoses, and previous antifungal therapy. Eligibility: People who were in prior NIH studies and had Candida Design: Researchers will review the records of 62 NIH participants. The records are from 2004 to 2017. They will look at data such as blood test results, diagnosis, and treatments. Researchers will only reach out to participants if they get approval from a review board. This research will probably not reveal data that would be important to participants health. But if it does, researchers will try to contact those participants. Data will be stored in secure computers. They will be stored with a code that only the study team can link to a participant.

NCT ID: NCT02734862 Completed - Fungal Infection Clinical Trials

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

STRIVE
Start date: July 26, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if intravenous CD101 is safe and effective in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by oral fluconazole).

NCT ID: NCT02719769 Completed - Bacteremia Clinical Trials

Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture

Start date: January 2016
Phase: N/A
Study type: Observational

The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST System for positive blood culture identification and susceptibility testing in a clinical setting. The data from this study will be used to support the 510(k) submission for FDA clearance and global registrations of the device intended for in vitro diagnostic use.

NCT ID: NCT02451592 Completed - Multiple Myeloma Clinical Trials

Fungemia in Hematologic Malignancies

Start date: January 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine the risk factors for fungemia in a population of patients diagnosed with hematologic malignancies and eligible for chemotherapy.

NCT ID: NCT01898208 Completed - Bacteremia Clinical Trials

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

Start date: August 2013
Phase: N/A
Study type: Interventional

Would rapid identification of bacteria and rapid detection of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE) (using an FDA-cleared assay) in positive blood culture bottles improve patient care at Mayo Clinic Rochester (or just lead to increased cost)?

NCT ID: NCT01450358 Completed - Sepsis Clinical Trials

Evaluation in the Treatment of Nosocomial Sepsis Comparing Polymerase Chain Reaction With Conventional Blood Culture.

Start date: January 2012
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the consumption of antimicrobial therapy in patients comparing a rapid molecular test (PCR in Real-Time Multiplex) with blood cultures to identify the etiological agents of sepsis.

NCT ID: NCT01359891 Completed - Sepsis Clinical Trials

Clinical Evaluation of Novel Biomarkers in Patients With Septicemia

NOBIS
Start date: November 2010
Phase:
Study type: Observational

The protein ST2 is a member of the interleukin-1 receptor family. Blood concentrations of the soluble isoform of ST2 (sST2) are increased in inflammatory and heart diseases and are considered a prognostic marker in both. The Presageā„¢ST2 assay was recently shown to meet the needs of quality specifications of laboratory medicine. Soluble urokinase plasminogen activator receptor (suPAR) levels reflect inflammation and elevated suPAR levels are found in several infectious diseases and cancer. Both sST2 and suPAR have recently been introduced as sensitive biomarkers for patients with septicemia. Both may be promising or even superior alternatives to currently established sepsis markers leading to an improvement of outcome in patients with septicemia. However, a clinical study which clarifies kinetics of values over time/possible correlation with causative pathogen/progress/deterioration of septic patients is urgently needed before these biomarkers can be established in clinical routine. Primary study objectives To clinically evaluate sST2 and suPAR in patients with bacteremia /septicemia. To correlate results with causative bacterial organisms, response to or failure of antiinfective treatment, severity of clinical status as well as outcome. To study the kinetics of the test results and to correlate the sST2/suPAR results with other well established infection markers (e.g. C-reactive protein, procalcitonin, blood counts). Natural endpoints of the study will be patient's death or complete recovery. This is an explorative study. To meet the objectives both novel biomarkers will be clinically evaluated in a cohort of 500 in-patients with septicemia at the University Hospital Graz. Starting the day a patient's blood culture turned positive the investigators will collect samples every 12h within the first two days and then every 24h.Measurement of sST2 and suPAR values will be done retrospectively. To analyze clinical sensitivity/specificity of the novel biomarkers sST2 and suPAR as prognostic factors for development of bacteremia/septicemia, a second cohort consisting of 250 in-patients will be investigated in a longitudinal matter. Patients without a previous positive blood culture test during the current episode of disease for which blood cultures are ordered by a physician will be included and sST2 and suPAR levels will be determined from samples taken simultaneously with this first blood cultures.

NCT ID: NCT01236261 Completed - Fungemia Clinical Trials

Prospective Population Study on Candidemia in Spain

CANDIPOP
Start date: March 2013
Phase: N/A
Study type: Observational

The aim of this study is to describe the epidemiology of fungal blood infections in Spain (with emphasis on the incidence, fungal species distribution and antifungal susceptibility). The study is to be performed in five big cities which represent different geographic areas: Barcelona, Bilbao, Madrid, Sevilla and Valencia.

NCT ID: NCT00841971 Completed - Mycoses Clinical Trials

Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients

Start date: February 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy of anidulafungin versus fluconazole for the prevention of fungal diseases in liver transplant recipients